Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies.
Multimodal profiling of pediatric T-ALL identifies broad but subtype-variable CD38 expression, links CD38 to polyamine metabolism, inflammatory signaling, and LCK activity, and reports improved survival in preclinical models when CD38 targeting is combined with DFMO or dasatinib.
Open original publication →What the AI sees
Multimodal profiling of pediatric T-ALL identifies broad but subtype-variable CD38 expression, links CD38 to polyamine metabolism, inflammatory signaling, and LCK activity, and reports improved survival in preclinical models when CD38 targeting is combined with DFMO or dasatinib.
Research significance
The supplied evidence supports preclinical activity for combining CD38-directed treatment with DFMO or dasatinib; it is reasonable—but not clinically demonstrated—to hypothesize that these combinations could enhance CD38-targeted therapy and potentially reduce relapse in pediatric T-ALL.
Source abstract
Outcomes for pediatric patients with refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) are poor, underscoring the need for improved therapeutic strategies. CD38, a type II transmembrane glycoprotein, is a promising target in T-ALL, with clinical trials evaluating CD38-targeting immunotherapies in frontline and relapsed settings. However, the biological role of CD38 in T-ALL has not been systematically defined. We interrogated CD38 biology through multimodal profiling of pediatric T-ALL samples. Bulk RNA sequencing of 1,335 primary tumors revealed that CD38 expression varies across genomic and immunophenotypic subtypes in T-ALL. Flow cytometry of 150 primary samples and CITE-sequencing of 40 cases demonstrated broad surface expression of CD38. A transcription factor CRISPR-screen identified RUNX1, RUNX3, and TP53 as candidate positive regulators of CD38. Metabolomic profiling of cell lines further revealed disruption of the polyamine pathway following CD38 perturbation. Supporting this finding, co-targeting CD38 with difluoromethylornithine (DFMO), a polyamine metabolism disruptor, improved survival in preclinical models. Across transcriptomic datasets, including primary tumors, cell lines, and patient-derived xenograft models, IL32 expression consistently decreased following CD38 loss or negativity, supporting an association between CD38 and inflammatory signaling pathways. Additionally, CD38 and LCK expression were positively correlated across majority of genomic subtypes, implicating SRC kinase signaling. Consistent with this, daratumumab in cell lines increased LCK phosphorylation, and combination therapy with dasatinib improved survival compared to monotherapy. Collectively, these findings define previously unrecognized interactions between CD38 and targetable pathways and genes in T-ALL and identify rational combinatorial strategies to enhance CD38-directed therapies and reduce relapse risk.